The Menarini Group and its oncology subsidiary, Stemline Therapeutics, have entered an exclusive worldwide licensing and collaboration agreement with Georgiamune to develop and commercialize GIM-621, an investigational oral immunotherapy being studied for its potential against multiple solid tumors. The agreement provides Georgiamune with $45 million in upfront and near-term payments. The biotechnology company is also eligible for additional preclinical, development, regulatory and commercial milestones, bringing the potential total deal value to $1.1 billion, plus royalties on sales.

GIM-621 is a preclinical-stage small molecule designed to modulate immune responses. The candidate emerged from Georgiamune’s research into the biological mechanisms that regulate immune-cell activation, suppression and homeostasis. Under the terms of the agreement, Stemline will hold exclusive global rights to develop, manufacture and commercialize the candidate. The partnership gives the program access to Menarini’s oncology development and commercial infrastructure as it advances toward potential clinical testing.

Samir N. Khleif, MD, Founder and CEO of Georgiamune, says the deal will allow Menarini to advance GIM-621 while his company continues developing a broader pipeline of therapies targeting immune signaling pathways in cancer and autoimmune diseases. The company currently has three other clinical-stage programs. These include GIM-407, an oral regulatory T-cell (Treg) activator being developed for autoimmune disease; GIM-122, a dual-functioning antibody for oncology; and GIM-531, an oral Treg inhibitor for cancer treatment. Menarini CEO Elcin Barker Ergun says GIM-621 complements the group’s solid tumor portfolio and that its oncology development and commercial capabilities could help advance the program.

The agreement adds another early-stage asset to Menarini’s oncology portfolio, while giving Georgiamune a partner with global development and commercialization capabilities. GIM-621 remains in preclinical development, and the companies have not disclosed a clinical trial timeline or specific tumor indications. Its potential application across multiple solid tumors will need to be evaluated through further research and development.

The collaboration reflects continued interest in immuno-oncology approaches that seek to influence immune-cell behavior through mechanisms beyond established treatment strategies. For Georgiamune, the deal provides a route to advance one of its emerging candidates while maintaining investment in its wider pipeline of immune-targeting therapies.

For further information, visit www.menarini.com.